pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2014-0-2-110-115pulmo-354Research ArticleОБЗОРЫREVIEWВОЗМОЖНОСТИ ПРИМЕНЕНИЯ АНТАГОНИСТОВ ЛЕЙКОТРИЕНОВЫХ РЕЦЕПТОРОВ ПРИ РАЗНЫХ ФЕНОТИПАХ БРОНХИАЛЬНОЙ АСТМЫLEUKOTRIENE RECEPTOR ANTAGONISTS IN DIFFERENT PHENOTYPES OF BRONCHIAL ASTHMAКняжескаяН. П.KnyazheskayaN. P.

к. м. н., доцент кафедры пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России; тел.: (910) 444-62-06

kniajeskaia@mail.ruГБОУ ВПО "Российский государственный медицинский университет им. Н.И.Пирогова" Минздрава России: 117997, Москва, ул. Островитянова, 1Russian Federation20142804201402110115Copyright © Княжеская Н.П., 20142014Княжеская Н.П.Knyazheskaya N.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/354

Цистеиниловые лейкотриены (Lt) – продукт липоксигеназного метаболизма арахидоновой кислоты – играют важную роль при всех фенотипах бронхиальной астмы (БА). Их высвобождение связано с иммунологической и неиммунологической стимуляцией различных клеток, им отводится значительная роль в формировании воспаления при БА. Lt вызывают бронхоконстрикцию, при которой увеличи-вается сосудистая проницаемость, усиливается отек слизистой бронхов, повышается секреция слизи. Изучение особенностей Lt как медиаторов воспаления позволило разработать и внедрить в клиническую практику антагонисты Lt-рецепторов. Их противовоспалительное действие позволяет достичь контролируемого течения БА как в виде монотерапии при легком течении БА, так и в комбинации с другими противоастматическими препаратами при более тяжелых формах заболевания. В настоящее время на основании изучения фенотипов БА определены те из них, в которых именно Lt имеют ключевое значение.

Cysteinyl leukotrienes which are products of lipoxygenase pathway of arachidonic acid metabolism play an important role in all phenotypes of bronchial asthma (BA). They are involved in immune and non-immune stimulation of different cells and inflammatory mechanisms in BA. Leukotrienes cause bronchoconstriction, increase vascular permeability and bronchial mucosa oedema, stimulate mucus secretion. Knowledge ofleukotriene as inflammation mediators has allowed development leukotriene receptor antagonists and their implementation in clinical practice. Antiinflammatory properties of leukotriene receptor antagonists facilitate achievement asthma control while using both as monotherapy in mild asthma and in combinations with other antiasthmatic drugs in more severe disease. Currently, ongoing research of asthma phenotypes could definecertain phenotypes with more important role of leukotrienes.

лейкотриеныантагонисты лейкотриеновых рецепторовмонтелукастфенотипы астмыleukotrienesleukotriene receptor antagonistsasthma phenotypesmontelukastReferencesGlobal Initiative for Asthma. Workshop Report, 2011. http://www.ginasthma.com/download.asp?intId=217Global Initiative for Asthma. Workshop Report, 2011. http://www.ginasthma.com/download.asp?intId=217Holgate S., Dahlen S-E., eds. SRS-A to Leukotrienes: The Dawning of a New Treatment. Oxford, UK: Blackwell Science Ltd; 1997.Holgate S., Dahlen S-E., eds. SRS-A to Leukotrienes: The Dawning of a New Treatment. Oxford, UK: Blackwell Science Ltd; 1997.O'Byrne P.M. Leukotrienes in the pathogenesis of asthma. Chest. 1997; 111: 27S–34S.O'Byrne P.M. Leukotrienes in the pathogenesis of asthma. Chest. 1997; 111: 27S–34S.Feldberg W., Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol. (Lond.). 1938; 94 (2): 187–226.Feldberg W., Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol. (Lond.). 1938; 94 (2): 187–226.Вылегжанина Т.Г. Взаимосвязь аллергического ринита и бронхиальной астмы. Consilium Medicum. 2001; 3 (12): 579–581. / Vylegzhanina T.G. A relationship between aller- gic rhinitis and bronchial asthma. Consilium Medicum. 2001; 3 (12): 579–581 (in Russian).Вылегжанина Т.Г. Взаимосвязь аллергического ринита и бронхиальной астмы. Consilium Medicum. 2001; 3 (12): 579–581. / Vylegzhanina T.G. A relationship between aller- gic rhinitis and bronchial asthma. Consilium Medicum. 2001; 3 (12): 579–581 (in Russian).Shore S. Obesity and asthma: lessons from animal models. J. Appl. Physiol. 2007; 102: 516–528.Shore S. Obesity and asthma: lessons from animal models. J. Appl. Physiol. 2007; 102: 516–528.Hernandez-Alvidrez E., Alba-Reyes G., Munoz-Cedillo B.C. et al. Passive smoking induces leukotriene production in children: influence of asthma. J. Asthma. 2013; 50 (4): 347–353.Hernandez-Alvidrez E., Alba-Reyes G., Munoz-Cedillo B.C. et al. Passive smoking induces leukotriene production in children: influence of asthma. J. Asthma. 2013; 50 (4): 347–353.Hedman J., Kaprio J., Poussa T. et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int. J. Epidemiol. 1999; 28: 717–722.Hedman J., Kaprio J., Poussa T. et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int. J. Epidemiol. 1999; 28: 717–722.Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J. Clin. Immunol. 1999; 104: 5–13.Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J. Clin. Immunol. 1999; 104: 5–13.Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 1990; 3: 588–593.Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 1990; 3: 588–593.McMains K.C., Kountakis S.E. Medical and surgical considerations in patients with Samter's triad. OceanSide Publications, Inc. Am. J. Rhinol. 2006; 20 (6): 573–576.McMains K.C., Kountakis S.E. Medical and surgical considerations in patients with Samter's triad. OceanSide Publications, Inc. Am. J. Rhinol. 2006; 20 (6): 573–576.Paganin F., Poubeau P., Yvin J.L. Arvin-Berod The effectiveness of leukotriene antagonists in the treatment o aspirinintolerant asthmatic patient. Presse Med. 2003; 32 (21): 978–984.Paganin F., Poubeau P., Yvin J.L. Arvin-Berod The effectiveness of leukotriene antagonists in the treatment o aspirinintolerant asthmatic patient. Presse Med. 2003; 32 (21): 978–984.Лопатин А.С., Гущин И.С., Емельянов А.В.и др. Клинические рекомендации по диагностике и лечению аллергического ринита. Consilium Medicum. 2001; Прил.: 33–44. / Lopatin A.S., Gushchin I.S., Emelyanov A.V. et al. Clinical guidelines on diagnosis and treatment of allergic rhinitis. Consilium Medicum. 2001; Pril.: 33–44 (in Russian).Лопатин А.С., Гущин И.С., Емельянов А.В.и др. Клинические рекомендации по диагностике и лечению аллергического ринита. Consilium Medicum. 2001; Прил.: 33–44. / Lopatin A.S., Gushchin I.S., Emelyanov A.V. et al. Clinical guidelines on diagnosis and treatment of allergic rhinitis. Consilium Medicum. 2001; Pril.: 33–44 (in Russian).Bjermer L., Anderson S.D. Bronchial hyperrcspoiisiveness in athletes: mechanisms for development. In: Carlsen K.H., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Icspiialoiy and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 19–34.Bjermer L., Anderson S.D. Bronchial hyperrcspoiisiveness in athletes: mechanisms for development. In: Carlsen K.H., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Icspiialoiy and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 19–34.Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy, March 2–4, 2006. ERS School Courses. 2006.Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy, March 2–4, 2006. ERS School Courses. 2006.Hallstrand T.S. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J. Pediatr. 2002; 141: 343–349.Hallstrand T.S. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J. Pediatr. 2002; 141: 343–349.Астафьева Н.Г. Астма и спорт. Consilium Medicum. 2008; 1:45–50. / Astaf`eva N.G. Astma and sport. Consilium Medicum. 2008; 1: 45–50 (in Russian).Астафьева Н.Г. Астма и спорт. Consilium Medicum. 2008; 1:45–50. / Astaf`eva N.G. Astma and sport. Consilium Medicum. 2008; 1: 45–50 (in Russian).Чучалин А.Г. Спорт и бронхиальная астма. Пульмонология и аллергология. 2005; 2: 3–5. / Chuchalin A.G. Sport and bronchial asthma. Pul'monologiya i allergologiya. 2005; 2: 3–5 (in Russian).Чучалин А.Г. Спорт и бронхиальная астма. Пульмонология и аллергология. 2005; 2: 3–5. / Chuchalin A.G. Sport and bronchial asthma. Pul'monologiya i allergologiya. 2005; 2: 3–5 (in Russian).Larsson K., Ohlsen P., Larsson L. et al. High prevalence of asthma in cross country skiers. Br. Med. J. 1993; 307: 1326–1329.Larsson K., Ohlsen P., Larsson L. et al. High prevalence of asthma in cross country skiers. Br. Med. J. 1993; 307: 1326–1329.Weiler J.M., Layton Ò., Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J. Allergy Clin. Immunol. 1998; 102: 722–6.Weiler J.M., Layton Ò., Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J. Allergy Clin. Immunol. 1998; 102: 722–6.Paiange R., Brusasco V., Delgado L., Del Giacco S. Exercise and airway pathology: interactions with immune and allergic responses. In: Carlsen Ê.Í., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Respiratory and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 10–18.Paiange R., Brusasco V., Delgado L., Del Giacco S. Exercise and airway pathology: interactions with immune and allergic responses. In: Carlsen Ê.Í., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Respiratory and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 10–18.Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57 (3): 226–230.Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57 (3): 226–230.Chaudhuri R., Livingston E., McMahon A.D. et al. Cigarette smoking impairs the therapeutic response to oralcorticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168 (11): 1308–1311.Chaudhuri R., Livingston E., McMahon A.D. et al. Cigarette smoking impairs the therapeutic response to oralcorticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168 (11): 1308–1311.Tomlinson J.E.M., McMahon A.D., Chaudhuri R. et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005; 60 (4): 282–287.Tomlinson J.E.M., McMahon A.D., Chaudhuri R. et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005; 60 (4): 282–287.Livingston E., Chaudhuri R., McMahon A.D. et al. Systemic sensitivity to corticosteroids in smokers withasthma. Eur. Respir. J. 2007; 29 (1): 64–71.Livingston E., Chaudhuri R., McMahon A.D. et al. Systemic sensitivity to corticosteroids in smokers withasthma. Eur. Respir. J. 2007; 29 (1): 64–71.Price D., Popov T.A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 2013; 131 (3): 763–771.Price D., Popov T.A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 2013; 131 (3): 763–771.Beuther D.A., Sutherland E.R. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care Med. 2007; 175: 661–666.Beuther D.A., Sutherland E.R. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care Med. 2007; 175: 661–666.Price D.B., Swern A., Tozzi C.A. et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–742.Price D.B., Swern A., Tozzi C.A. et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–742.Keith P.K., Koch C., Djandji M. et al.Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can. Respir. J. 2009; 16 (Suppl. A): 17A–31A.Keith P.K., Koch C., Djandji M. et al.Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can. Respir. J. 2009; 16 (Suppl. A): 17A–31A.Bjermer L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 23–30.Bjermer L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 23–30.Chen X., Wang K., Jiang M., Nong G.M. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J. Asthma 2013; 50 (7): 695–704.Chen X., Wang K., Jiang M., Nong G.M. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J. Asthma 2013; 50 (7): 695–704.Vaquerizo M.J., Casan P., Castillo J. et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58: 211–216.Vaquerizo M.J., Casan P., Castillo J. et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58: 211–216.Virchow J.C., Mehta A., Ljungblad L., Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast. In Chronic Asthma (MONICA) study. Respir. Med. 2010; 104 (5): 644–651.Virchow J.C., Mehta A., Ljungblad L., Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast. In Chronic Asthma (MONICA) study. Respir. Med. 2010; 104 (5): 644–651.Bisgaard H., Skoner D., Boza M.L. et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr. Pulmonol. 2009; 44 (6): 568–579.Bisgaard H., Skoner D., Boza M.L. et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr. Pulmonol. 2009; 44 (6): 568–579.Knorr B., Nguyen H.H., Kearns G.L. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J. Clin. Pharmacol. 2001; 41 (6): 612–619.Knorr B., Nguyen H.H., Kearns G.L. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J. Clin. Pharmacol. 2001; 41 (6): 612–619.Wechsler M.E., Pauwels R., Drazen J.M. Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999; 21: 241–251.Wechsler M.E., Pauwels R., Drazen J.M. Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999; 21: 241–251.Stirling R.G., Chung .KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax. 1999; 54: 865–866.Stirling R.G., Chung .KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax. 1999; 54: 865–866.Solans R., Bosch J.A., Perez-Bocanegra C. et al. Churg–Strauss syndrome: outcome and long-term follow up of 32 patients. Rheumatology. 2001; 40: 763–771.Solans R., Bosch J.A., Perez-Bocanegra C. et al. Churg–Strauss syndrome: outcome and long-term follow up of 32 patients. Rheumatology. 2001; 40: 763–771.

The authors declare that there are no conflicts of interest present.